insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

EDSA · Edesa Biotech, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · EDSA

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ2 '26Q1 '26Q3 '25Q2 '25Q1 '25Q3 '24Q2 '24Q1 '24Q3 '23Q2 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$2.77M$1.12M$939.1K$484.3K$1.02M$897.3K$1.18M$704.5K$1.03M$1.46M
SG&A$1.53M$1.22M$964.7K$1.15M$878.9K$1.04M$1.04M$1.15M$1.04M$952.4K
Total Operating Expenses----------
D&A-$25.5K--$45.0K--$45.0K--
Operating Income($4.30M)($2.34M)($1.90M)($1.64M)($1.90M)($1.93M)($2.22M)($1.86M)($2.06M)($2.41M)
Interest Expense----------
Income Tax$800-$0$800-$0$800-$0$800
Net Income($4.22M)($2.25M)($1.75M)($1.59M)($1.62M)($1.67M)($1.86M)($1.68M)($1.98M)($2.33M)
EPS - Basic($0.49)($0.28)($0.25)($0.58)($0.54)($0.68)----
EPS - Diluted----------

Balance Sheet

Line itemQ2 '26Q1 '26Q3 '25Q2 '25Q1 '25Q3 '24Q2 '24Q1 '24Q3 '23Q2 '23
Cash & Equivalents$10.00M$12.10M$10.80M$13.90M$1.60M$1.00M$2.80M$4.27M$5.40M$7.47M
Accounts Receivable----------
Inventory----------
Accounts Payable----------
Current Assets$10.42M$12.72M$11.51M$14.39M$2.07M$1.68M$4.24M$5.42M$6.44M$8.13M
Total Assets$12.38M$14.71M$13.53M$16.45M$4.16M$3.81M$6.48M$7.83M$8.89M$10.67M
Current Liabilities$2.19M$756.2K$1.08M$914.7K$1.90M$1.83M$2.15M$1.99M$1.82M$1.56M
Long-term Debt----------
Total Liabilities-----$1.83M$2.15M$1.99M$1.84M$1.67M
Stockholders' Equity$10.20M$13.95M$12.45M$15.54M$2.26M$1.98M$4.32M$5.84M$7.05M$9.00M
Retained Earnings($72.45M)($68.20M)($65.91M)($61.86M)($60.23M)($58.59M)($55.96M)($54.10M)($52.42M)($48.71M)

Cash Flow

Line itemQ2 '26Q1 '26Q3 '25Q2 '25Q1 '25Q3 '24Q2 '24Q1 '24Q3 '23Q2 '23
Operating Cash Flow-($2.09M)--($1.52M)--($1.41M)--
Investing Cash Flow-------$0--
Financing Cash Flow-$3.36M--$2.07M--$305.7K--
CapEx----------
Free Cash Flow----------

Ratios

MetricQ2 '26Q1 '26Q3 '25Q2 '25Q1 '25Q3 '24Q2 '24Q1 '24Q3 '23Q2 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-34.1%-15.3%-12.9%-9.7%-38.8%-43.7%-28.7%-21.4%-22.3%-21.9%
Return on equity-41.4%-16.1%-14.0%-10.2%-71.4%-84.2%-43.0%-28.7%-28.2%-25.9%
Return on invested capital----------
Liquidity
Current ratio4.7616.8210.6715.731.090.911.972.733.535.20
Quick ratio4.7616.8210.6715.731.090.911.972.733.535.20
Cash ratio4.5716.0010.0115.200.840.551.302.152.964.77
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.211.051.091.061.841.931.501.341.261.19
Liabilities / Assets-----0.480.330.250.210.16
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-162.2%-23.3%1.5%26.2%-2.2%6.4%7.9%21.9%64.4%47.3%
Net income growth (YoY)-165.2%-39.0%-4.9%14.6%3.6%16.0%20.3%28.1%65.7%48.9%
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-34.4%516.4%528.5%259.4%-61.3%-71.9%-52.0%-43.1%-24.9%-47.1%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Edesa Biotech against the 5 most active filers in the same SIC group.